WITHUS PHARMACEUTICALLTD Past Earnings Performance
Past criteria checks 3/6
WITHUS PHARMACEUTICALLTD's earnings have been declining at an average annual rate of -14.9%, while the Pharmaceuticals industry saw earnings growing at 10.1% annually. Revenues have been growing at an average rate of 9.9% per year. WITHUS PHARMACEUTICALLTD's return on equity is 10.1%, and it has net margins of 10.2%.
Key information
-14.9%
Earnings growth rate
-79.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 9.9% |
| Return on equity | 10.1% |
| Net Margin | 10.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings
May 25
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability
Dec 09Recent updates
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings
May 25Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like
Feb 17Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)
Jan 13
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability
Dec 09Revenue & Expenses Breakdown
How WITHUS PHARMACEUTICALLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 90,147 | 9,194 | 42,922 | 1,517 |
| 31 Dec 23 | 80,119 | 7,959 | 37,347 | 1,868 |
| 30 Sep 23 | 68,975 | 3,264 | 34,399 | 2,067 |
| 30 Jun 23 | 65,794 | 1,606 | 32,112 | 2,410 |
| 31 Mar 23 | 63,032 | 1,057 | 30,742 | 2,615 |
| 31 Dec 22 | 64,680 | 2,479 | 29,849 | 2,357 |
| 30 Sep 22 | 64,618 | 5,424 | 27,797 | 2,108 |
| 30 Jun 22 | 62,461 | 5,282 | 27,136 | 1,852 |
| 31 Mar 22 | 61,564 | 5,089 | 26,754 | 1,586 |
| 31 Dec 21 | 57,419 | 4,264 | 26,328 | 1,420 |
| 31 Dec 20 | 53,406 | 6,652 | 22,807 | 1,807 |
| 30 Sep 20 | 52,842 | 7,075 | 22,229 | 1,983 |
| 30 Jun 20 | 52,393 | 8,039 | 21,150 | 1,512 |
| 31 Mar 20 | 53,743 | 8,742 | 21,974 | 1,149 |
| 30 Jun 19 | 51,732 | 8,661 | 20,158 | 587 |
| 30 Jun 18 | 50,945 | 8,491 | 19,302 | 0 |
| 30 Jun 17 | 49,519 | 7,332 | 19,112 | 0 |
| 30 Jun 16 | 45,878 | 7,844 | 17,542 | 0 |
| 30 Jun 15 | 41,640 | 7,147 | 12,440 | 0 |
| 30 Jun 14 | 39,192 | 6,372 | 12,588 | 0 |
Quality Earnings: A330350 has a high level of non-cash earnings.
Growing Profit Margin: A330350's current net profit margins (10.2%) are higher than last year (1.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A330350's earnings have declined by 14.9% per year over the past 5 years.
Accelerating Growth: A330350's earnings growth over the past year (769.8%) exceeds its 5-year average (-14.9% per year).
Earnings vs Industry: A330350 earnings growth over the past year (769.8%) exceeded the Pharmaceuticals industry 18.9%.
Return on Equity
High ROE: A330350's Return on Equity (10.1%) is considered low.